Aesthetics

This week in aesthetics, a study examines tofacitinib to treat alopecia areata, Dr. Michael Kluska compares Renuvion (J-Plasma) versus Bodytite, and more.

The American Society of Dermatologic Surgery releases its annual survey showing the continued popularity of minimally invasive and nonsurgical treatments.

A 2017 study examines the long-term efficacy of JAK 1/3 inhibitor, tofacitinib, for treatment of alopecia areata and its variants.

This week, consumer magazines highlight the science behind the longevity movement for aging, dermarolling for hair loss, and more.

This week in aesthetics, we highlight collagen supplements for anti-aging, plastic surgery safety during COVID-19, and more.

Merz and Candela announce the launch of a commercial collaboration to provide one of the broadest medical aesthetics portfolios in the world.

A recent study examines plastic surgery safety data to verify COVID-19 protocols.

For aesthetic physicians interested in incorporating regenerative medicine into the practice, we’ve compiled a list of 5 articles to inform and inspire, including novel applications and how to get started.

BENEV recently announced positive results in its study examining the combination therapy of human adipose tissue stem cell-derived exosomes and fractional CO2 laser for the treatment of acne scars.

Allergan Aesthetics has entered into a warrant agreement that will give the company an option to acquire Cypris Medical following the completion of a clinical trial evaluating Cypris’ Xact device.

Endo Aesthetics announces the launch of its new, “Really Cellulite” campaign to eliminate the shame associated with cellulite.

Researchers examine the results of collagen supplements for both short- and long-term anti-aging use.

A recent study shows an association between finasteride use and psychological adverse events (AEs) including suicidality. Dermatologists should weigh benefits and risks carefully when considering finasteride for certain patients with hair loss, according to one expert.

This week, consumer magazines highlight PCOS-related cystic acne, psychodermatology, and more.

This week in aesthetics, a study examines energy device plume, the U.S. International Trade Commission upholds a 21-month ban on Evolus’ Jeuveau, and more.

ASDS releases guidance on reported cases of adverse events related to the Moderna COVID-19 vaccine and dermal filler patients.

In 2020, injectables saw improvements in consultations, combination therapy, and more.

The U.S. International Trade Commission recently announced it will uphold the ban on Jeuveau, changing its original sentence from 10 years to 21 months.

A new guidance from the American Society for Dermatologic Surgery (ASDS) has been released regarding side effects from the SARS-CoV-2 mRNA vaccine on dermal fillers.

Revance Therapeutics announces positive results from its phase 2 multicenter, open-label study investigating DaxibotulinumtoxinA (DAXI) as an injectable treatment for glabellar lines, lateral canthal lines and dynamic forehead lines

Notable partnerships in aesthetic medicine include that of Candela and Jabil, Revance and HintMD, among others.

Hydrafacial and Vesper Healthcare recently announced they have entered into a definitive merger agreement expected to close in the first half of 2021.

FDA approvals in 2020 included Galderma’s Restylane Kysse, Endo Aesthetics QWO for cellulite, and more.

Revance Therapeutics announces positive phase 2 DAXI results and provides an update on expected FDA Approval.

InMode recently announced study results comparing fractional RF vs. Er:YAG plume for transmission risk of COVID-19.